X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (14) 14
humans (11) 11
index medicus (11) 11
aged (8) 8
carcinoma, non-small-cell lung - drug therapy (8) 8
female (8) 8
carcinoma, non-small-cell lung - genetics (7) 7
disease-free survival (7) 7
gefitinib (7) 7
lung neoplasms - drug therapy (7) 7
lung neoplasms - genetics (7) 7
middle aged (7) 7
antineoplastic agents - therapeutic use (6) 6
mutation (6) 6
adult (5) 5
erbb receptors - genetics (5) 5
male (5) 5
aged, 80 and over (4) 4
double-blind method (4) 4
kaplan-meier estimate (4) 4
protein kinase inhibitors - therapeutic use (4) 4
quinazolines - therapeutic use (4) 4
survival (4) 4
therapy (4) 4
treatment outcome (4) 4
acquired-resistance (3) 3
analysis (3) 3
antineoplastic agents, hormonal - administration & dosage (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
azd9291 (3) 3
breast cancer (3) 3
breast neoplasms - drug therapy (3) 3
carboplatin - administration & dosage (3) 3
carcinoma, non-small-cell lung - pathology (3) 3
drug administration schedule (3) 3
endocrine therapy (3) 3
erlotinib (3) 3
estradiol - administration & dosage (3) 3
estradiol - analogs & derivatives (3) 3
lung cancer, non-small cell (3) 3
lung neoplasms - pathology (3) 3
open-label (3) 3
paclitaxel - administration & dosage (3) 3
piperazines - therapeutic use (3) 3
survival rate (3) 3
adenocarcinoma (2) 2
adenocarcinoma - drug therapy (2) 2
adenocarcinoma - genetics (2) 2
adenocarcinoma - pathology (2) 2
afatinib (2) 2
anastrozole (2) 2
antineoplastic agents - adverse effects (2) 2
aromatase inhibitors - administration & dosage (2) 2
asia (2) 2
brain metastases (2) 2
breast neoplasms - metabolism (2) 2
breast neoplasms - pathology (2) 2
cancer (2) 2
carcinoma, non-small-cell lung - mortality (2) 2
care and treatment (2) 2
cell biology (2) 2
cell lung-cancer (2) 2
chemotherapy (2) 2
clinical trials (2) 2
drug therapy (2) 2
efficacy (2) 2
egfr mutation (2) 2
egfr-tki (2) 2
epidermal growth factor (2) 2
epidermal growth factor receptors (2) 2
erbb receptors - antagonists & inhibitors (2) 2
estrogen receptor modulators - administration & dosage (2) 2
exanthema - chemically induced (2) 2
fulvestrant (2) 2
hematology, oncology and palliative medicine (2) 2
lung cancer (2) 2
lung neoplasms - mortality (2) 2
lung-cancer (2) 2
medical research (2) 2
metastasis (2) 2
non-small cell lung carcinoma (2) 2
non-small-cell lung cancer (2) 2
nsclc (2) 2
odds ratio (2) 2
oncology, experimental (2) 2
oncology-group (2) 2
patients (2) 2
previously treated patients (2) 2
proportional hazards models (2) 2
pulmonary/respiratory (2) 2
quinazolines - adverse effects (2) 2
quinazolines - pharmacology (2) 2
randomized controlled trials as topic (2) 2
receptor, epidermal growth factor - genetics (2) 2
research (2) 2
respiratory system (2) 2
skin rash (2) 2
tumors (2) 2
tyrosine (2) 2
tyrosine kinase (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 01/2018, Volume 378, Issue 2, pp. 113 - 125
In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | CNS RESPONSE | AZD9291 | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Gefitinib | Lung Neoplasms - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Survival Rate | Piperazines - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Cancer patients | Care and treatment | Lung cancer, Non-small cell | Analysis | Tyrosine | Medical research | Epidermal growth factor receptors | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Oncology | Metastasis | Gene deletion | Patients | Cancer therapies | Clinical outcomes | Chemotherapy | Epidermal growth factor | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2011, Volume 29, Issue 21, pp. 2866 - 2874
Purpose The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and carboplatin/paclitaxel in previously untreated never-smokers and light... 
TRIAL | CHEMOTHERAPY-NAIVE PATIENTS | FACTOR-RECEPTOR GENE | PLACEBO | ONCOLOGY-GROUP | ONCOLOGY | TYROSINE KINASE | SENSITIVITY | EGFR MUTATIONS | MOLECULAR PREDICTORS | PREVIOUSLY TREATED PATIENTS | Immunohistochemistry | Lung Neoplasms - drug therapy | Predictive Value of Tests | Adenocarcinoma - pathology | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Time Factors | Gefitinib | Odds Ratio | Paclitaxel - administration & dosage | Adenocarcinoma - chemistry | Precision Medicine | ErbB Receptors - antagonists & inhibitors | Lung Neoplasms - chemistry | Risk Assessment | Risk Factors | Carboplatin - administration & dosage | In Situ Hybridization, Fluorescence | Logistic Models | Survival Rate | Adenocarcinoma - drug therapy | Biomarkers, Tumor - genetics | Mutation | Carcinoma, Non-Small-Cell Lung - chemistry | Adenocarcinoma of Lung | ErbB Receptors - genetics | Lung Neoplasms - pathology | Patient Selection | Female | Adenocarcinoma - genetics | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Biomarkers, Tumor - analysis | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Gene Dosage | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | ErbB Receptors - analysis | Adenocarcinoma - mortality
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2017, Volume 35, Issue 36, pp. 4027 - 4034
Purpose The Iressa Mutation-Positive Multicentre Treatment Beyond ProgRESsion Study (IMPRESS) compared the continuation of gefitinib plus chemotherapy with... 
BRAIN METASTASES | EGFR MUTATION | NSCLC | ONCOLOGY
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2018, Volume 36, Issue 33, pp. 3290 - 3297
PurposeWe report CNS efficacy of osimertinib versus standard epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with... 
SURVIVAL | IMPACT | THERAPY | EFFICACY | ONCOLOGY | BRAIN METASTASES | ACQUIRED-RESISTANCE | AZD9291
Journal Article
Cancer Research, ISSN 0008-5472, 05/2015, Volume 75, Issue 9 Supplement, pp. P1 - P1-13-02
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 05/2015, Volume 33, Issue 15, pp. TPS8102 - TPS8102
Conference Proceeding
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 04/2019, Volume 25, Issue 7, pp. 2058 - 2063
Purpose:In the phase III FLAURA study, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib significantly... 
ONCOLOGY
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 08/2019
To assess the utility of the EGFR Mutation Test, with tissue and plasma, for first-line osimertinib therapy for patients with -mutated ( m) (Ex19del and/or... 
Journal Article
Lung Cancer, ISSN 0169-5002, 2013, Volume 81, Issue 2, pp. 280 - 287
Journal Article
Lung Cancer, ISSN 0169-5002, 2016, Volume 104, pp. 119 - 125
Highlights • IPASS: open-label study of first-line gefitinib vs carboplatin/paclitaxel in NSCLC. • IPASS confirmed that EGFR mutation status predicted response... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | Non-small-cell lung cancer | Epidermal growth factor receptor tyrosine kinase inhibitor | IPASS study | Epidermal growth factor receptor-mutation positive | SURVIVAL | ADENOCARCINOMA | OPEN-LABEL | positive | Epidermal growth factor receptor tyrosine | Epidermal growth factor receptor-mutation | CELL LUNG-CANCER | kinase inhibitor | ONCOLOGY | RESPIRATORY SYSTEM | CLINICALLY SELECTED PATIENTS | AFATINIB | Lung Neoplasms - drug therapy | Adenocarcinoma - pathology | Paclitaxel - pharmacology | Humans | Middle Aged | ErbB Receptors - genetics | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Aged, 80 and over | Female | Quinazolines - administration & dosage | Adenocarcinoma - genetics | Gefitinib | Paclitaxel - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Randomized Controlled Trials as Topic | Disease-Free Survival | Asian Continental Ancestry Group | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Smoking - epidemiology | Aged | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Carboplatin - pharmacology | Neoplasm Staging | Quinazolines - pharmacology | Medical research | Analysis | Medicine, Experimental | Respiratory tract diseases | Genetic aspects | Lung cancer, Non-small cell
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.